GAL-3、CK19、HBME-1在甲状腺乳头状癌诊断中的应用价值  

Diagnostic values of Gal-3、CK19、HBME-1 in papillary thyroid carcinoma

作　　者：陈帅[1] 任建强[1] 潘炯[1] 

机构地区：[1]上海市第一人民医院宝山分院普外科,200940

出　　处：《实用医学杂志》2012年第22期3692-3694,共3页The Journal of Practical Medicine

摘　　要：目的:通过比较Gal-3(Galectin-3)、CK19、HBME-1在甲状腺乳头状癌及良性甲状腺病变中表达的差异,探讨这三种分子标志物在甲状腺乳头状癌诊断应用中的价值。方法:免疫组化Envision二步法检测80例甲状腺乳头状癌和80例良性甲状腺组织中Gal-3、CK19、HBME-1三者的表达情况。结果:Gal-3、CK19、HBME-1在甲状腺乳头状癌中表达的阳性率分别为:92.5%(73/80)、97.5%(78/80)、96.3%(77/80),绝大多数强阳性表达;在甲状腺良性病变中的阳性表达率分别为:27.5%(22/80)、16.3%(13/80)、13.8%(11/80);正常甲状腺组织均表达为阴性。三种分子标记联合检测用于区别甲状腺乳头状癌及良性病变其灵敏度为:76.0%,特异度为100.0%,正确率为88.0%。结论:Gal-3、CK19、HBME-1在甲状腺乳头状癌中的表达显著高于良性病变,其检测有助于甲状腺乳头状癌及甲状腺良性病变之间的鉴别诊断。Objective To investigate the applications of Gal-3 （Galectin-3）,CK19,HBME-1 in the diagnosis of papillary thyroid carcinoma by studying the different expression patterns of three molecular makers in papillary thyroid carcinoma and benign thyroid lesions. Methods Immunohistochemical staining methods （EnVision two-step Visualization Systems） were used to detect the expression of Gal-3,CK19,HBME-1 in 80 cases of PTC and 80 cases of benign thyroid lesions. Results The expressions of Gal-3,CK19 and HBME-1 were identified in 92.5% （73/80）,97.5% （78/80） and 96.3% （77/80） of PTC cases, and in 27.5% （22/80）, 16.3% （13/80） and 13.8% （11/80） of benign thyroid lesions cases. High expressions of the three molecular makers were found, in most of the PTC cases, but not found in normal thyroid specimens. The sensitivity, specificity and accuracy of the joint detection of the three molecular makers for distinguishing between PTC＇ and benign lesions were 85.0%, 100.0% and 92.5%, respectively. Conclusions The expressions of Gal-3,CK19,HBME-1 in PTC were significantly higher than those in benign lesions, which is helpful in distinguishing between PTC and benign lesions.

关 键 词：甲状腺乳头状癌 GALECTIN-3 HBME-1 CK19 免疫组化 

分 类 号：R736.1[医药卫生—肿瘤]